Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Henar Hevia, PhD, Senior Director, EMEA Therapy Area Head, Oncology, Johnson & Johnson Innovative Medicine, said: “The subcutaneous formulation of amivantamab reflects our ongoing commitment to ...

Patients with newly diagnosed GCA waited an average of 43 days to start subcutaneous tocilizumab, paying an average of $1023 out-of-pocket for the first month of treatment. Patients with newly ...

SAN DIEGO, CA—Use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) appears to have some advantages over transvenous devices for patients with an ICD indication but no need for pacing, ...

With Skyrizi now capturing 1 in 3 in place UC patients, we highlight that the company’s I&I portfolio appears poised to continue growing through more significant Humira erosion,” analyst Evan ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due to any cause or persistence of cancer cells by 32% in patients with ...

The LifeSite Hemodialysis System (Vasca, Inc., Tewksbury, MA, USA)is totally subcutaneous, incorporating two silicone catheters positioned in the central venous system and connected to a stainless ...

Today, a brief rundown of news involving Merck and Vanda Pharmaceuticals, as well as updates from Sanofi and Novo Holdings that you may have missed. Novartis and BioMarin Pharmaceutical, in striking ...

Background: The PRAETORIAN trial investigated the efficacy and safety of the subcutaneous implantable cardioverter-defibrillator (S-ICD) compared with transvenous ICD (TV-ICD) and showed ...

In a lawsuit filed Thursday in a New Jersey federal court, Halozyme alleges that a proposed subcutaneous formulation of Merck’s popular cancer drug Keytruda infringes 15 of its patents.

SAN DIEGO, April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug ...